Devices

In the SWEET project experience, a large cohort of patients was started on either an insulin pump, glucose sensor, or both to compare the HbA1c levels and weight gain while on their new therapy.

The seventh-generation (G7) continuous glucose monitor provides accurate and safe glucose readings during 10.5 days of use among adults that have diabetes. 

Results from using GlucosePATH in Medicaid patients reveal the benefits of clinical decision support software in reducing HbA1c, reducing the risk of disease complications, and improving access to care. 

Fitness trackers are affordable and popular, but do they correlate with better physical activity levels in people with diabetes or other with cardiometabolic conditions?

Digital health companies have innovated ways to help individuals eat healthily and make better food choices.

Smart contact lenses are capable of tracking tear glucose levels and delivering drug therapy directly to the retina.

Maintaining proper skincare can help in preventing infections when using diabetes devices.

There is not much evidence-based literature on point-of-care devices, yet they are commonly used for diagnosis. 

Evaluating the discordance between laboratory and continuous glucose monitoring estimated HbA1c.

Alternative site placement of continuous glucose monitor device is assessed in the hospital setting.